www.fdanews.com/articles/149546-pharma-blog-watch
Pharma Blog Watch
September 18, 2012
Incorrectly Attacking Pharma’s Business Model (World of DTC Marketing blog)
“I guess it’s easy to jump on the bandwagon and throw rocks at big pharma today,” blogger Rich Meyer writes. “The author of a British Medical Journal’s article has not done his research or really thought through what is really happening in healthcare and pharma in particular.” One point the BMJ author made was that the FDA approves new drugs as “safe” and “effective” when industry-friendly regulations prohibit the FDA from using comparative effectiveness to approve new drugs. Myer disagrees. “I’m not sure why he thinks this is true but the fact remains that the FDA approves new drugs based on required clinical studies and ongoing clinical studies,” he writes. “The bottom line is that there are risks and benefits of ALL prescription drugs.”
“I guess it’s easy to jump on the bandwagon and throw rocks at big pharma today,” blogger Rich Meyer writes. “The author of a British Medical Journal’s article has not done his research or really thought through what is really happening in healthcare and pharma in particular.” One point the BMJ author made was that the FDA approves new drugs as “safe” and “effective” when industry-friendly regulations prohibit the FDA from using comparative effectiveness to approve new drugs. Myer disagrees. “I’m not sure why he thinks this is true but the fact remains that the FDA approves new drugs based on required clinical studies and ongoing clinical studies,” he writes. “The bottom line is that there are risks and benefits of ALL prescription drugs.”